GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of SUPN
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Friday for Supernus Pharmaceuticals stock after gaining 1.84%
(Updated on Apr 19, 2024)

Sell candidate since Apr 08, 2024 Loss -6.46% PDF

The Supernus Pharmaceuticals stock price gained 1.84% on the last trading day (Friday, 19th Apr 2024), rising from $28.87 to $29.40. During the last trading day the stock fluctuated 3.00% from a day low at $28.67 to a day high of $29.53. The price has fallen in 6 of the last 10 days and is down by -12.37% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 11 thousand more shares were traded than the day before. In total, 339 thousand shares were bought and sold for approximately $9.96 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $28.96 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 16.95% during the next 3 months and, with a 90% probability hold a price between $33.86 and $43.15 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

SUPN Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, April 18, 2024, and so far it has risen 1.84%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Supernus Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $29.85 and $32.27. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Supernus Pharmaceuticals stock

Supernus Pharmaceuticals finds support from accumulated volume at $29.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.86 between high and low, or 3.00%. For the last week, the stock has had daily average volatility of 3.26%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (SUPN) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect Supernus Pharmaceuticals to open at $29.20, and during the day (based on 14 day Average True Range), to move between $28.19 and $30.61, which gives a possible trading interval of +/-$1.21 (+/-4.13%) up or down from last closing price. If Supernus Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 8.25% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $29.00 (1.36%) than the resistance at $30.69 (4.39%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Supernus Pharmaceuticals stock A Buy?

The Supernus Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Supernus Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.788 Sell Candidate Unchanged

Predicted Opening Price for Supernus Pharmaceuticals of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$29.20 ( 0.680%) $29.40

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for SUPN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 30.06 2.24 %
R2 29.73 1.13 %
R1 29.53 0.437 %
Current price: 29.40
Support S1 28.87 -1.80 %
S2 28.67 -2.49 %
S3 28.34 -3.61 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 31.43 6.90 %
R2 31.08 5.71 %
R1 30.69 4.39 %
Current price 29.40
Support S1 29.00 -1.36%
S2 28.41 -3.37%
S3 28.35 -3.57%

FAQ

What is the symbol for Supernus Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Supernus Pharmaceuticals is SUPN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Supernus Pharmaceuticals Stock?
The Supernus Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Supernus Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Supernus Pharmaceuticals Stock?
Supernus Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Supernus Pharmaceuticals Stock.

What's the current price of Supernus Pharmaceuticals Stock?
As of the end of day on the 2024-04-19, the price of an Supernus Pharmaceuticals (SUPN) share was $29.40.

What is the 52-week high and low for Supernus Pharmaceuticals Stock?
The 52-week high for Supernus Pharmaceuticals Stock is $39.09 and the 52-week low is $22.00.

What is the market capitalization of Supernus Pharmaceuticals Stock?
As of the 2024-04-19, the market capitalization of Supernus Pharmaceuticals is 1.609B.

When is the next earnings date for Supernus Pharmaceuticals?
The upcoming earnings date for Supernus Pharmaceuticals is May 14, 2024.
Click to get the best stock tips daily for free!

About Supernus Pharmaceuticals

Supernus Pharmaceuticals Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr... SUPN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT